Astria TherapeuticsATXS
ATXS
About: Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Employees: 78
0
Funds holding %
of 7,457 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
46% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 13
3% more funds holding
Funds holding: 110 [Q4 2024] → 113 (+3) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
0.62% less ownership
Funds ownership: 103.81% [Q4 2024] → 103.18% (-0.62%) [Q1 2025]
8% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 36
41% less capital invested
Capital invested by funds: $524M [Q4 2024] → $311M (-$213M) [Q1 2025]
86% less call options, than puts
Call options by funds: $5K | Put options by funds: $36K
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$16
304%
upside
Avg. target
$33
728%
upside
High target
$47
1,087%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Cantor Fitzgerald Timur Ivannikov 100% 1-year accuracy 2 / 2 met price target | 1,087%upside $47 | Overweight Reiterated | 14 May 2025 |
Cantor Fitzgerald Steven Seedhouse 0% 1-year accuracy 0 / 8 met price target | 1,087%upside $47 | Overweight Initiated | 29 Apr 2025 |
Wedbush Laura Chico 23% 1-year accuracy 10 / 44 met price target | 607%upside $28 | Outperform Maintained | 12 Mar 2025 |
HC Wainwright & Co. Joseph Pantginis 20% 1-year accuracy 75 / 369 met price target | 304%upside $16 | Buy Reiterated | 11 Mar 2025 |
Citizens Capital Markets Jonathan Wolleben 49% 1-year accuracy 30 / 61 met price target | 557%upside $26 | Market Outperform Reiterated | 3 Mar 2025 |
Financial journalist opinion
Based on 4 articles about ATXS published over the past 30 days
Neutral
Business Wire
4 days ago
Astria Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. “As a late-stage clinical company, we are focused on delivering on navenibart, a therapy with a trusted mechanism and modality, best-in-class profile, and the potential to change the way that people live with H.
Neutral
Business Wire
2 weeks ago
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 33,650 shares of Astria's common stock on May 1, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were granted.
Neutral
Business Wire
2 weeks ago
Astria Therapeutics Announces Publication of Navenibart Phase 1a Healthy Subject Results in the Annals of Allergy, Asthma & Immunology
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that results from a Phase 1a trial in healthy subjects supporting navenibart's potential to provide long-acting, safe, and effective attack prevention for hereditary angioedema (HAE) with dosing every 3 and 6 months have been published in the Annals of Allergy, Asthma & Immunology. “We are thrilled.
Neutral
Business Wire
2 weeks ago
Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Citizens Life Sciences Conference on Wednesday, May 7th at 10:30am ET. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jmp65/atxs/1702976. An archived repl.
Neutral
Business Wire
1 month ago
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 43,650 shares of Astria's common stock on April 1, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were grante.
Neutral
Business Wire
2 months ago
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. “2025 promises to be an exciting year for Astria, and we are building on the momentum from a successful 2024 with the initiation of two important clinical trials,” said Jill C. Milne, Ph.D., C.
Neutral
Business Wire
2 months ago
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 87,450 shares of Astria's common stock on March 3, 2025 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria. The options were grante.
Neutral
Business Wire
2 months ago
Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the initiation of the ALPHA-ORBIT Phase 3 clinical trial of navenibart in people living with hereditary angioedema (HAE). Navenibart has the potential to provide rapid and sustained HAE attack prevention with a very low treatment burden and administration every 3 months (Q3M) and every 6 months (Q6M). “.
Neutral
Business Wire
2 months ago
Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th at 9:50am ET in Boston, MA. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/cowen177/atxs.
Neutral
Business Wire
2 months ago
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress
BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present three posters at the American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress in San Diego, California on March 2, 2025. Markus Magerl, M.D., Professor of Dermatology and Allergy at the Charité Universitätsmedizin Berlin Institut.
Charts implemented using Lightweight Charts™